[Adverse effects and drugs for Alzheimer's disease].
Molecules currently available or in late phases of development for the treatment of Alzheimer's disease have modest and apparently equivalent efficacies. Thus, the choice will depend on the safety profile of these drugs and on the patient characteristics. The aim of this review is to undertake an inventory of adverse effects and interactions reported in the literature for anticholinesterasics (the only ones approved by authorities). As most of the molecules described in this article are still in early phases of development, data reported here mainly issued from clinical trials carried out on specific populations. Most of these reported adverse effects have not been attributed according to the rules of pharmacovigilance. Nevertheless, we believe that the data presented in this review will be of great interest to clinicians and pharmacovigilance specialists as the compounds concerned become available on the market.
Unité Fonctionnelle de Pharmaco-épidémiologie, Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Rennes, France.
S
S
Schück
D
D
Bentué-Ferrer
C
C
Beaufils
E
E
Polard
S
S
Belliard
H
H
Allain
D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000009:adverse effects*; D006801:Humans; D018697:Nootropic Agents / Q000009:adverse effects*
D002800:Cholinesterase Inhibitors; D018697:Nootropic Agents
Effets indésirables et médicaments de la maladie d'Alzheimer.